Alpine Immune Sciences Presents New Preclinical Data on Povetacicept in Myasthenia Gravis at the American Association of Neuromuscular & Electrodiagnostic Medicine 2023 Annual Meeting
03 Novembro 2023 - 10:00AM
Business Wire
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading
clinical-stage immunotherapy company focused on developing
innovative treatments for autoimmune and inflammatory diseases,
announced the Company presented new preclinical data on
povetacicept in myasthenia gravis at the American Association of
Neuromuscular & Electrodiagnostic Medicine Annual Meeting
(AANEM), November 1-3, 2023 in Phoenix, Arizona. In addition, the
Company presented safety, tolerability, pharmacokinetic, and
pharmacodynamic data from RUBY-1, a phase 1 study of povetacicept
in healthy adult volunteers.
Key Takeaways:
- In a model of murine experimental autoimmune myasthenia gravis
(EAMG), povetacicept improved disease activity, with clinical
scores superior to treatment with either the FcRn inhibitor
efgartigimod or an anti-CD20 depleting antibody. It also reduced
anti-AChR IgG autoantibodies and serum Ig isotypes, including IgM
and IgA, superior to both comparator treatments.
- In the RUBY-1 clinical trial, povetacicept was well tolerated
in adult healthy volunteers as single intravenous or subcutaneous
doses of up to 960 mg and exhibited dose-related pharmacokinetic
and pharmacodynamic effects, including reductions in circulating Ig
and antibody-secreting cells. The results support the use of an
every four-week subcutaneous dosing regimen in future therapeutic
studies.
“Relatively few approved drugs appear to be directed at the
underlying disease pathogenesis of myasthenia gravis,” said
Stanford Peng, MD PhD, President and Head of Research and
Development at Alpine. “These data indicate that povetacicept might
deliver efficacy superior to some therapeutics currently in
clinical use for myasthenia gravis and other autoantibody-related
neurological diseases. Given the encouraging clinical data we
presented earlier this week with povetacicept in
glomerulonephritis, particularly IgA nephropathy, we look forward
to exploring other indications such as myasthenia gravis where
povetacicept may be an active and convenient, yet potentially
disease-modifying, treatment.”
American Association of Neuromuscular
& Electrodiagnostic Medicine (AANEM) Annual Meeting
Date/Time: Thursday, November 2, 2023, 6:00pm – 6:30pm PT
and Friday, November 3, 2023 at 3:00pm – 3:30pm PT Poster
Title: Povetacicept (ALPN-303), a Potent Dual BAFF/APRIL
Antagonist, for the Treatment of Myasthenia Gravis (MG) and Other
Antibody-Related Diseases Poster Board Number: 207
Location: Poster Hall, JW Marriott Phoenix Desert Ridge
Presenter: Marcia Friedman, M.D., Associate Medical
Director, Alpine Immune Sciences
About Povetacicept (ALPN-303)
Povetacicept (ALPN-303) is a dual antagonist of the BAFF (B cell
activating factor) and APRIL (a proliferation inducing ligand)
cytokines, which play key roles in pathogenesis of multiple
autoimmune diseases via their roles in the activation,
differentiation and/or survival of B cells, particularly
antibody-secreting cells, as well as T cells and innate immune
cells. Based upon an engineered TACI (transmembrane activator and
CAML interactor) domain, povetacicept has exhibited greater potency
in preclinical studies versus wild-type TACI-based comparators, as
well as other inhibitors of BAFF and/or APRIL alone and B cell
depletion. Povetacicept is in development for multiple autoimmune
diseases, including IgA nephropathy and other autoimmune kidney
diseases, systemic lupus erythematosus, and autoimmune
cytopenias.
About Alpine Immune
Sciences
Alpine Immune Sciences is committed to leading a new wave of
immune therapeutics. With world-class research and development
capabilities, a highly productive scientific platform, and a proven
management team, Alpine is seeking to create first- or
best-in-class multifunctional immunotherapies via unique protein
engineering technologies to improve patients’ lives. Alpine has
entered into strategic collaborations with leading global
biopharmaceutical companies and has a diverse pipeline of clinical
and preclinical candidates in development. For more information,
visit www.alpineimmunesciences.com. Follow @AlpineImmuneSci on
Twitter and LinkedIn.
Forward-Looking
Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are
not based on historical fact and include statements regarding our
platform technology and potential therapies; the timing of and
results from clinical trials and preclinical development
activities; clinical and regulatory objectives and the timing
thereof; expectations regarding the sufficiency of cash, cash
equivalents, restricted cash, and investments to fund our planned
operations through 2025; the potential efficacy, safety profile,
future development plans, addressable market, regulatory success,
and commercial potential of our product candidates; our ability to
achieve additional milestones in our collaborations and proprietary
programs; the progress and potential of our ongoing development
programs; the timing of our public presentations and potential
publication of future clinical data; the efficacy of our clinical
trial designs; anticipated enrollment in our clinical trials and
the timing thereof; expectations regarding our ongoing
collaborations; and our ability to successfully develop and achieve
milestones in our development programs. Forward-looking statements
generally include statements that are predictive in nature and
depend upon or refer to future events or conditions and include
words such as “may,” “will,” “should,” “would,” “expect,” “plan,”
“intend,” and other similar expressions, among others. These
forward-looking statements are based on current assumptions that
involve risks, uncertainties, and other factors that may cause
actual results, events, or developments to be materially different
from those expressed or implied by such forward-looking statements.
These risks and uncertainties, many of which are beyond our
control, include, but are not limited to: clinical trials may not
demonstrate safety and efficacy of any of our product candidates;
our ongoing discovery and preclinical efforts may not yield
additional product candidates; our discovery-stage and preclinical
programs may not advance into the clinic or result in approved
products; any of our product candidates may fail in development,
may not receive required regulatory approvals, or may be delayed to
a point where they are not commercially viable; we may not achieve
additional milestones in our proprietary or partnered programs; the
impact of competition; adverse conditions in the general domestic
and global economic markets; the impact of pandemics, or other
related health crises on our business, research and clinical
development plans and timelines and results of operations,
including the impact on our clinical trial sites, collaborators,
and contractors who act for or on our behalf; as well as the other
risks identified in our filings with the Securities and Exchange
Commission. These forward-looking statements speak only as of the
date hereof and we undertake no obligation to update
forward-looking statements, and readers are cautioned not to place
undue reliance on such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231103537555/en/
Media and Investor Relations
Contact: Temre Johnson Alpine Immune Sciences, Inc.
ir@alpineimmunesciences.com media@alpineimmunesciences.com
Alpine Immune Sciences (NASDAQ:ALPN)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Alpine Immune Sciences (NASDAQ:ALPN)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024